Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 232

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

Open access
El Osta, Badi, Behera, Madhusmita, Kim, Sungjin, Berry, Lynne D., Sica, Gabriel, Pillai, Rathi N., Owonikoko, Taofeek K., Kris, Mark G., Johnson, Bruce E., Kwiatkowski, David J., Sholl, Lynette M., Aisner, Dara L., Bunn, Paul A., Khuri, Fadlo R., Ramalingam, Suresh S.·2019·Journal of Thoracic Oncology
DOI 10.1016/j.jtho.2019.01.020
Open this paper in CoChat — free account

Abstract

Introduction: Mutations in the KRAS gene are the most common driver oncogenes present in lung adenocarcinomas. We analyzed the largest multi‐institutional database available containing patients with metastatic KRAS‐mutant lung adenocarcinomas. Methods: The Lung Cancer Mutation Consortium (LCMC) is a multi‐institutional collaboration to study the genomic characteristics of lung adenocarcinomas, treat them with genomically directed therapeutic approaches, and assess their outcomes. Since its inception in 2009, the LCMC has enrolled more than 1900 patients and has performed pretreatment, multiplexed, molecular characterization along with collecting clinical data. We evaluated the characteristics of patients with KRAS mutation in the LCMC and the association with overall survival. Results: Data from 1655 patients with metastatic lung adenocarcinomas were analyzed. Four hundred fifty (27%) patients had a KRAS mutation, 58% were female, 93% were smokers, and there was a median age of 65 years. Main KRAS subtypes were: G12C 39%; and G12D and G12V at 18% each. Among patients with KRAS mutation, G12D had a higher proportion of never‐smokers (22%, p < 0.001). Patients with KRAS‐mutant tumors had a trend toward shorter median survival compared to all others in the series (1.96 versus 2.22; P = 0.08) and lower 2‐year survival rate (49% [95% confidence interval: 44%–54%] and 55% [95% confidence interval: 52%–58%], respectively). Conclusions: In the LCMC study, 27% of lung adenocarcinomas patients harbored a KRAS mutation and up to one‐third of them had another oncogenic driver. Patients with both KRAS and STK11 mutations had a significantly inferior clinical outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2019.01.020

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 19

  1. Planchard, 2016, Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non–small cell lung cancer: an open-label, multicentre phase 2 trial, Lancet Oncol, 17, 984, 10.1016/S1470-2045(16)30146-2 · DOI · Paper page
  2. Riely, 2008, KRAS mutations: an old oncogene becomes a new predictive biomarker, J Mol Diagn, 10, 493, 10.2353/jmoldx.2008.080105 · DOI
  3. Saito, 2016, Gene aberrations for precision medicine against lung adenocarcinoma, Cancer Sci, 107, 713, 10.1111/cas.12941 · DOI · Paper page
  4. Slebos, 1990, K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung, N Engl J Med, 323, 561, 10.1056/NEJM199008303230902 · DOI · Paper page
  5. Yu, 2015, Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas, J Thorac Oncol, 10, 431, 10.1097/JTO.0000000000000432 · DOI
  6. Johnson, 2013, Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas, Cancer, 119, 356, 10.1002/cncr.27730 · DOI · Paper page
  7. Mascaux, 2005, The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis, Br J Cancer, 92, 131, 10.1038/sj.bjc.6602258 · DOI · Paper page
  8. Eberhard, 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non–small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib, J Clin Oncol, 23, 5900, 10.1200/JCO.2005.02.857 · DOI · Paper page
  9. Massarelli, 2007, KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer, Clin Cancer Res, 13, 2890, 10.1158/1078-0432.CCR-06-3043 · DOI · Paper page
  10. Douillard, 2010, Molecular predictors of outcome with gefitinib and docetaxel in previously treated non–small-cell lung cancer: data from the randomized phase III INTEREST trial, J Clin Oncol, 28, 744, 10.1200/JCO.2009.24.3030 · DOI · Paper page
  11. Ihle, 2012, Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome, J Natl Cancer Inst, 104, 228, 10.1093/jnci/djr523 · DOI · Paper page
  12. Davies, 2007, Mol Cancer Ther, 6, 2209, 10.1158/1535-7163.MCT-07-0231 · DOI · Paper page
  13. Janne, 2013, Selumetinib plus docetaxel for KRAS-mutant advanced non–small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study, Lancet Oncol, 14, 38, 10.1016/S1470-2045(12)70489-8 · DOI · Paper page
  14. Zdanov, 2016, Mutant KRAS conversion of conventional T cells into regulatory T cells, Cancer Immunol Res, 4, 354, 10.1158/2326-6066.CIR-15-0241 · DOI · Paper page
  15. Sholl, 2015, Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience, J Thorac Oncol, 10, 768, 10.1097/JTO.0000000000000516 · DOI · Paper page
  16. Cox, 1972, Regression models and life tables, J Royal Stat Society, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x · DOI · Paper page
  17. Yamashita, 2007, A stepwise AIC method for variable selection in linear regression, Comm Statistics Theory Methods, 36, 2395, 10.1080/03610920701215639 · DOI · Paper page
  18. Chaft, 2017, Neoadjuvant nivolumab in early-stage, resectable non–small cell lung cancers, J Clin Oncol, 35, 8508, 10.1200/JCO.2017.35.15_suppl.8508 · DOI
  19. Wang, 2016, Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK, Nat Commun, 7, 11363, 10.1038/ncomms11363 · DOI

Cited by

See all 232

Metadata

Authors
El Osta, B., Behera, M., Kim, S., Berry, L. D., Sica, G., Pillai, R. N., Owonikoko, T. K., Kris, M. G., Johnson, B. E., Kwiatkowski, D. J., Sholl, L. M., Aisner, D. L., Bunn, P. A., Khuri, F. R., & Ramalingam, S. S.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2019-05
Volume
14
Issue
5
Pages
876-889
ISSN
1556-0864 (ISSN-L)
DOI
10.1016/j.jtho.2019.01.020
OpenAlex
W2911842472
Cited by
232
References
13
FWCI
19.44
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • Winship Cancer Institute
  • Merck
  • Bristol-Myers Squibb
  • Loxo Oncology
  • Novartis
  • International Business Machines Corporation
  • G1 Therapeutics
  • AbbVie
  • Pfizer
  • Bavarian Nordic
  • Lung Cancer Research Foundation
  • Boehringer Ingelheim
  • Genentech
  • AstraZeneca

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. https://app.cochat.ai/papers/10.1016/j.jtho.2019.01.020
The paper
El Osta, B., Behera, M., Kim, S., Berry, L. D., Sica, G., Pillai, R. N., Owonikoko, T. K., Kris, M. G., Johnson, B. E., Kwiatkowski, D. J., Sholl, L. M., Aisner, D. L., Bunn, P. A., Khuri, F. R., & Ramalingam, S. S. (2019). Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2019.01.020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.